



Miami University Institutional Biosafety Committee (IBC) Meeting Minutes

December 16, 2025 Meeting Minutes

Location: Zoom

Members Present:

- Dr. Joseph Carlin (Chair, Microbiology)
- Mr. Jeffrey Johnson (Environmental Health and Safety)
- Ms. Jazzminn Hembree (Animal Expert, Laboratory Animal Resources)
- Dr. Rock Mancini (Chemistry & Biochemistry)
- Dr. Richard Page (Associate Vice President of Research and Innovation, *ex officio*)
- Dr. Carole Dabney-Smith (Plant Expert, Chemistry & Biochemistry)
- Dr. Tom Crist (Department of Biology)
- Ms. Patricia Mueller (Unaffiliated Member)
- Dr. Matthew Saxton (Biological Sciences)
- Dr. Andrew Jones (Chemical, Paper, and Biomedical Engineering)

Members Absent:

- Ms. Carol Durrough (Unaffiliated Member)

Staff Present:

- Ms. Amanda Stewart (Assistant Director of Lab Safety)

Guests Present:

- None

I. Call to Order

- a. 3:00 p.m.
- b. Quorum established. Nine voting members present.
- c. Conflict of Interest Statement: IBC members with a conflict of interest related to the review of a specific application may not be involved in the review or approval of the application if the IBC member expects to be engaged in research described in the application or has a direct financial interest.

II. Review of Previous Meeting Minutes

- a. Review of meeting minutes from October 18, 2025.
 - i. Comments: None
 - ii. Motion to approve.
 - iii. Vote: For: 9; Against: 0; Abstain: 0; Absent: 1

III. Announcements

- a. None

IV. Reports of Non-Compliance or Incidents

- a. None reported.

V. Protocol Review

- a. Application Title: Miami0059_Borkar_2025_10_07 - Continued

- i. Principal Investigator: Dr. Chandrashekhar Borkar
- ii. Primary Reviewer Name: [IBC Member]
- iii. Additional Reviewer(s) Name(s): N/A
- iv. Project Overview:

The survival of an animal depends on its ability to select appropriate behaviors in response to rapidly changing environmental conditions. To increase survival chances, animals must learn from both positive and negative outcomes and adjust their behavior accordingly. The proposed study addressed a fundamental question: how the brain processes sensory information and uses it to guide behavior. While the roles of broad brain regions are relatively well understood, how specific neuronal circuits, defined by particular cell types and pathways, control behavior is less known. Understanding these mechanisms at both the neurological and circuit level will not only build fundamental knowledge, but also guide us to discover new approaches to treat the psychiatric conditions associated with anxiety, trauma and mood disorders.

- v. Agent Names:

1. pAAV-hSyn-EGFP
2. AAV-Flex-ta-CasP3-TEVP
3. AAV-CMV-FLEX-SaCas9-U6-sgCrh
4. pGP-AAV-syn-FLEX-jGCaMP8f-WPRE
5. AAV9-hsyn-DIO-NE2h
6. pAAV-hSyn-dF-HA-KORD-IRES-mCitrine
7. rAAV-pgk-Cre
8. pAAV-hSyn-hM4D(Gi)-mCherry
9. AAV-EF1a-DIO-hChR2(H134R)-EYFP-WPRE-HGHpa
10. pAAV8-hSyn-DIO-hm3D(Gq)-mCherry
11. pAAV8-hSyn-DIO-hm4d(Gi)-mCherry
12. pAAV-EF1a-DIO-EYFP
13. pAAV_hSyn_WiChR_TS_mScarlet_ER
14. pAAV-hSyn-DIO-mCherry
15. pAAV-EF1a-DIO-eNpHR3.0-EYFP
16. pAAV-Syn-ChrimsonR-tdT
17. Murine tissue
18. Cholera Toxin Subunit B, Alexa Fluor 488 Conjugate

- vi. BSL: Biosafety Level 1

- vii. Applicable NIH Guidelines: Section III-E-3
- viii. Potential for Dual-Use: No
- ix. Training Assigned:
 - 1. Basic Introduction to Biosafety
 - 2. Viral Vectors Module 1: Risk Assessment
 - 3. Viral Vectors Module 4: Adenoviral Vector
 - 4. Viral Vectors Module 5: Adeno-Associated Viral/AAV Vector
- x. Risk Assessment and Discussion:
 - 1. The IBC members discussed the research description and indicated that IACUC approval was required before the IBC would issue an approval letter.
 - 2. The IBC members discussed the revisions submitted by the PI and determined that the revisions submitted were sufficient.
 - 3. The IBC members indicated that a safety plan was required for the use of 4-Hydroxytamoxifen. The Office of Research and Innovation and the Environmental Health and Safety Office indicated that a safety plan will be created and reviewed by the Director of Laboratory Animals Resources, IBC Chair, and IACUC Chair.
- xi. Information to be communicated with PI:
 - 1. None
- xii. IBC Lab Assessment Results:
 - 1. Site assessment was completed on November 12, 2025.
- xiii. Motion: Motion to approve with notification to the PI after IACUC approval.
- xiv. Vote: For: 9; Against: 0; Abstain: 0; Absent: 1

VI.New Business

- a. The NIH Office of Science Policy contacted the Office of Research and Innovation regarding the submission of the URL for the IBC meeting minutes webpage in the IBC Registration Management System (IBC-RMS). The Office of Research and Innovation submitted the requested information.

VII.Old Business

- a. None.

VIII.IBC Training and Continuing Education

- a. National Institutes of Health, Office of Science Policy. Animal experiments covered under the *NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules*.
https://osp.od.nih.gov/wp-content/uploads/2022/11/Animal_Activities_Table.pdf

IX.Meeting Adjournment

- a. 3:17 p.m.